<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="367517">
  <stage>Registered</stage>
  <submitdate>28/11/2014</submitdate>
  <approvaldate>10/12/2014</approvaldate>
  <actrnumber>ACTRN12614001289606</actrnumber>
  <trial_identification>
    <studytitle>Using the chemicals in the human body to predict the optimal dose of orally administered anticancer drugs.</studytitle>
    <scientifictitle>An investigation of the proportional change in plasma concentration of endogenous compounds relative to a pathway probe for CYP3A4 (midazolam) when administered with and without enzyme inducers and inhibitors, in healthy adult volunteers. </scientifictitle>
    <utrn />
    <trialacronym>EPOC-15</trialacronym>
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Pharmacology
</healthcondition>
    <healthcondition>Oncology</healthcondition>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2>Research that is not of generic health relevance and not applicable to specific health categories listed above</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Administration of a single dose of midazolam (1mg; oral tablet) on three occasions on study days 0,7 and 14. Administration of rifampicin 300mg oral tablet once daily for 7 days on study days 1 to 7. Administration of ciprofloxicin 250mg oral tablet twice daily for three days on study Days 11 to 13 .</interventions>
    <comparator>Not Applicable</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Early detection / Screening</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Midazolam concentrations-time profile. Plasma-midazolam concentrations will be determined by LC-MS.</outcome>
      <timepoint>Sampling to occur at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4 and 6 hours post administration of midazolam on each study day (days 0, 7 and 14).</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Plasma concentrations of endogenous compounds. Plasma concentrations of endogenous compounds will be determined by LC-MS.</outcome>
      <timepoint>Sampling to occur prior to midazolam administration on each study day (days 0, 7 and 14).</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>None</outcome>
      <timepoint>None</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Healthy
Non-smoker
BMI in the range 18 to 30</inclusivecriteria>
    <inclusiveminage>21</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>35</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>1. Use of prescription, over-the-counter, complimentary or recreational drugs during seven days prior and for the duration of the study. Paracetamol is permitted.
2. Current cigarette smoker.
3. Consumption of grapefruit juice in the period 48 hours prior and for the duration of the study.
4. Prior allergy or adverse reaction to any of the drugs used in the study.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Diagnosis</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>28/07/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>78</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
    <hospital>Flinders Medical Centre - Bedford Park</hospital>
    <postcode>5042 - Bedford Park</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Flinders University</primarysponsorname>
    <primarysponsoraddress>Flinders Drive
Bedford Park
South Australia 5042</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Flinders University</fundingname>
      <fundingaddress>Flinders Drive
Bedford Park
South Australia 5042</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Identify an endogenous metabolic phenotype for the enzyme CYP3A4 that can be used as a component of a pathway phenotyping panel to optimise anticancer drug dosing</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Southern Adelaide Clinical Human Research Ethics Committee</ethicname>
      <ethicaddress>Flinders Medical Center
Flinders Drive
Bedford Park
South Australia 5042</ethicaddress>
      <ethicapprovaldate>3/03/2015</ethicapprovaldate>
      <hrec>11.15 - HREC/15/SAC/5</hrec>
      <ethicsubmitdate>15/12/2014</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Andrew Rowland</name>
      <address>Department of Clinical Pharmacology Flinders Medical Centre Flinders Drive Bedford Park South Australia 5042</address>
      <phone>+61 8 8204 7546</phone>
      <fax />
      <email>andrew.rowland@flinders.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Madele van Dyk</name>
      <address>Department of Clinical Pharmacology Flinders Medical Centre Flinders Drive Bedford Park South Australia 5042</address>
      <phone>+61 8 8204 3155</phone>
      <fax />
      <email>vand0307@flinders.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Andrew Rowland</name>
      <address>Department of Clinical Pharmacology Flinders Medical Centre Flinders Drive Bedford Park South Australia 5042</address>
      <phone>+61 8 8204 7546</phone>
      <fax />
      <email>andrew.rowland@flinders.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>